Data / Form D filings / Biommune Technologies Inc.
Biommune Technologies Inc.: Form D filing
Biommune Technologies Inc., a biotechnology company in Vancouver, British Columbia, Canada, filed a Form D with the SEC in 2015. The latest, on November 30, 2015, reports $600,000 sold of a $600,000 offering to 3 investors.
Find out what Biommune Technologies Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- Suite 1780 - 400 Burrard St., Vancouver, British Columbia, Canada, V6C 3
- Phone
- (778) 389-2936
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- British Columbia, Canada
- Year incorporated
- 2011
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1659574
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 30, 2015 | New notice | $600,000 | $600,000 | $0 | 3 | Nov 18, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Karoly Nikolich | Director | |
| Terry Pearson | Director | |
| PATRICK W. GRAY | Executive Officer | |
| Reinhard Gabathuler | Executive Officer | |
| JENS BIERTUMPEL | Director | |
| Judi Dalling | Executive Officer | |
| Rob Hutchison | Director | |
| Michael Hutchison | Director |
Every Form D from the week of Nov 30, 2015 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Biommune Technologies Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.